NADAC acquisition cost data for ARISTADA ER 1,064 MG/3.9 ML SYR. This is a brand-name medication — generic alternatives may be available at lower prices.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 65757040403 | $860.02 | 2022-04-01 | Rx |
| 65757040403 | $860.02 | 2022-04-01 | Rx |
| 65757040403 | $860.02 | 2022-04-01 | Rx |
| 65757040403 | $860.02 | 2022-04-01 | Rx |
| 65757040403 | $860.02 | 2022-04-01 | Rx |
| 65757040403 | $860.02 | 2022-04-01 | Rx |
| 65757040403 | $860.02 | 2022-04-01 | Rx |
| 65757040403 | $860.02 | 2022-04-01 | Rx |
| 65757040403 | $860.02 | 2022-04-01 | Rx |
| 65757040403 | $860.02 | 2022-04-01 | Rx |
Generic: Aripiprazole Lauroxil | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $160.4M | 64,806 | 10,992 | $827.20 |
| 2020 | $203.1M | 76,175 | 11,836 | $872.71 |
| 2021 | $230.4M | 82,292 | 12,813 | $911.60 |
| 2022 | $256.9M | 88,507 | 13,161 | $945.40 |
| 2023 | $272.9M | 90,583 | 13,295 | $980.72 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| California | $23.7M | 7,954 | 1,212 |
| Ohio | $17.0M | 5,584 | 828 |
| Texas | $16.5M | 5,254 | 912 |
| New York | $16.4M | 5,407 | 853 |
| Missouri | $13.2M | 4,444 | 611 |
| Arizona | $11.2M | 3,828 | 591 |
| Florida | $11.0M | 3,576 | 616 |
| North Carolina | $8.7M | 2,759 | 418 |
| Wisconsin | $8.6M | 2,841 | 395 |
| Iowa | $8.4M | 2,726 | 393 |
| Pennsylvania | $8.2M | 2,741 | 453 |
| Michigan | $7.5M | 2,641 | 465 |
| Illinois | $7.0M | 2,368 | 358 |
| Indiana | $6.8M | 2,218 | 348 |
| Virginia | $6.7M | 2,224 | 342 |
| Tennessee | $6.1M | 1,986 | 322 |
| Louisiana | $6.0M | 1,970 | 298 |
| Massachusetts | $5.9M | 2,233 | 354 |
| Oklahoma | $5.8M | 1,888 | 289 |
| Alabama | $5.5M | 1,772 | 274 |
| New Jersey | $4.9M | 1,569 | 245 |
| Georgia | $4.6M | 1,527 | 237 |
| Arkansas | $4.5M | 1,467 | 222 |
| Utah | $4.3M | 1,498 | 202 |
| South Carolina | $4.0M | 1,325 | 173 |
| Mississippi | $3.9M | 1,288 | 196 |
| Washington | $3.8M | 1,284 | 200 |
| New Mexico | $3.4M | 1,257 | 204 |
| Kansas | $3.2M | 1,067 | 155 |
| Kentucky | $3.0M | 992 | 166 |
| Nebraska | $2.9M | 904 | 134 |
| Maryland | $2.8M | 931 | 184 |
| South Dakota | $2.7M | 889 | 109 |
| Colorado | $2.5M | 830 | 142 |
| Hawaii | $2.2M | 731 | 94 |
| Delaware | $2.1M | 675 | 111 |
| Idaho | $2.1M | 674 | 126 |
| Minnesota | $2.1M | 678 | 111 |
| Oregon | $1.9M | 657 | 107 |
| Connecticut | $1.6M | 562 | 79 |
| Rhode Island | $1.4M | 514 | 84 |
| Nevada | $1.4M | 478 | 68 |
| New Hampshire | $1.2M | 393 | 53 |
| District of Columbia | $1.2M | 370 | 59 |
| Montana | $1.1M | 361 | 54 |
| West Virginia | $871.5K | 282 | 52 |
| Maine | $775.5K | 264 | 47 |
| Alaska | $683.0K | 221 | 46 |
| North Dakota | $617.3K | 191 | 29 |
| Wyoming | $412.9K | 151 | 17 |
| Vermont | $151.5K | 51 | 11 |
| Puerto Rico | $42.6K | 16 | N/A |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.